ArticleDiscover oncology2026
Fascin-1 expression in non-small cell lung cancer and its diagnostic implications.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Currently, a systematic explanation of the clinical application and diagnostic value of Fascin-1 (FSCN1) in lung cancer has not been established. This study used immunohistochemistry (IHC) to detect the expression level of FSCN1 protein in 276 cases of non-small cell lung cancer (NSCLC) tissues, to explore the clinical value of FSCN1 and its diagnostic value in distinguishing between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). FSCN1 expression was analyzed in normal lung tissues, LUAD, and LUSC. The positivity rates were 0.0% (0/41) in normal tissues, 50.9% (85/167) in LUAD, and 98.2% (107/109) in LUSC. Furthermore, strong positivity was observed in 0.0% (0/41), 19.8% (33/167), and 93.6% (102/109) of these tissue groups, respectively. Both the overall positivity and the strong positivity rates of FSCN1 were significantly higher in LUSC than in either LUAD or normal lung tissues. ROC curve analysis demonstrated that FSCN1 positivity and strong positivity effectively discriminated LUSC, with areas under the curve (AUC) of 0.736 (95% CI: 0.679-0.794; P < 0.001) and 0.869 (95% CI: 0.824-0.914; P < 0.001), respectively. In LUAD, FSCN1 positive expression was significantly associated with male gender, tumor size >3 cm, poor differentiation, lymph node metastasis, and higher tumor stage. Similarly, FSCN1 strong positive expression was associated with male gender, tumor size >3 cm, poor differentiation, and smoking history. Multiple logistic regression analysis identified that independent predictors of FSCN1 positive expression in LUAD included poorly differentiated tumors (OR = 2.576; 95% CI: 1.085-6.114; P = 0.032) and higher tumor stage (OR = 2.316; 95% CI: 1.205-4.453; P = 0.012). Meanwhile, independent predictors of FSCN1 strong positive expression included male gender (OR = 3.036; 95% CI: 1.376-6.700; P = 0.006). Survival analysis revealed that FSCN1 positivity was significantly associated with reduced 5-year relapse-free survival (RFS) in LUAD patients (P = 0.025), though no significant association was observed with overall survival (OS). These findings indicate that FSCN1 may play an important role in lung cancer pathogenesis and progression, and could serve as a differential diagnostic marker between LUSC and LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.